These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36995071)

  • 21. Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.
    Abutayeh RF; Taha MO
    J Mol Graph Model; 2019 May; 88():128-151. PubMed ID: 30703688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
    Ko B; Jang Y; Kim MH; Lam TT; Seo HK; Jeong P; Choi M; Kang KW; Lee SD; Park JH; Kim M; Han SY; Kim YC
    Eur J Med Chem; 2023 Dec; 262():115860. PubMed ID: 37866334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
    Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
    Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
    Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
    J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
    Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
    Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
    Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
    [No Abstract]   [Full Text] [Related]  

  • 28. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
    Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
    J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
    Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
    J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel approach for relapsed/refractory FLT3
    Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
    Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
    Jones LM; Melgar K; Bolanos L; Hueneman K; Walker MM; Jiang JK; Wilson KM; Zhang X; Shen J; Jiang F; Sutter P; Wang A; Xu X; Tawa GJ; Hoyt SB; Wunderlich M; O'Brien E; Perentesis JP; Starczynowski DT; Thomas CJ
    J Clin Invest; 2020 Apr; 130(4):2017-2023. PubMed ID: 32149729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
    Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
    Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
    Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
    Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S; Mesli F; Fatima Zohra HA; Nacereddine C; Hadjer C; Abdellatif M
    J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.
    Alafnan A; Dogan R; Bender O; Celik I; Mollica A; Malik JA; Rengasamy KRR; Break MKB; Khojali WMA; Alharby TN; Atalay A; Anwar S
    Eur Rev Med Pharmacol Sci; 2023 Apr; 27(8):3270-3287. PubMed ID: 37140277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.